Definium Therapeutics, Inc. (DFTX) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon. I am Geeta Jain, Head of Investor Relations, and thank you for joining us today for DFINIUM Therapeutics' first quarter, 2026, financial results and recent highlights conference call. Currently, all participants are in listen-only mode. This webcast is live on the investor section of DFINIUM's website at DFINIUMTX.com, and a replay will be available after the webcast. Leading the call today will be Rob Barrow, our Chief Executive Officer, who is joined by Dr. Dan Carlin, our Chief Medical Officer, Brandy Roberts, our Chief Financial Officer, and Matt Wiley, our Chief Commercial Officer. During today's call, we will be making certain forward-looking statements, including without limitation statements about the potential safety, efficacy, and regulatory and clinical progress of our product candidates, our anticipated cash runaway, and our future expectations, plans, partnerships, and prospects. These statements are subject to various risks, such as changes in market conditions and difficulties associated with research and development and regulatory approval processes. These and other risk factors are described in the filings made with the SEC and the applicable Canadian securities regulators, including our annual report on Form 10-K and our Form 10-Q filed today. Forward-looking statements are based on assumptions, opinions, and estimates of management at the date the statements are made. including the non-occurrence of the risks and uncertainties that are described in the filings made with the SEC and the applicable Canadian securities regulators or other significant events occurring outside of DFINIUM's normal course of business. Your caution not to place undue reliance on these forward-looking statements, which are made as of today, May 7th, 2026. DF...